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Abstract
Autism spectrum disorder (ASD) is a markedly heterogeneous condition with a varied phenotypic 
presentation. Its high concordance among siblings, as well as its clear association with specific 
genetic disorders, both point to a strong genetic etiology. However, the molecular basis of ASD is 
still poorly understood, although recent studies point to the existence of sex-specific ASD 
pathophysiologies and biomarkers. Despite this, little is known about how exactly sex influences 
the gene expression signatures of ASD probands. In an effort to identify sex-dependent biomarkers 
and characterise their function, we present an analysis of a single paired- end post-mortem brain 
RNA-Seq data set and a meta-analysis of six blood-based microarray data sets. Here, we identify 
several genes with sex-dependent dysregulation, and many more with sex-independent 
dysregulation. Moreover, through pathway analysis, we find that these sex-independent 
biomarkers have substantially different biological roles than the sex-dependent biomarkers, and 
that some of these pathways are ubiquitously dysregulated in both post- mortem brain and blood. 
We conclude by synthesizing the discovered biomarker profiles with the extant literature, by 
*
 samleenz@me.com; contacttomquinn@gmail.com. 
HHS Public Access
Author manuscript
Am J Med Genet B Neuropsychiatr Genet. Author manuscript; available in PMC 2020 
September 01.
Published in final edited form as:
Am J Med Genet B Neuropsychiatr Genet. 2019 September ; 180(6): 377–389. doi:10.1002/ajmg.b.
32701.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
highlighting the advantage of studying sex-specific dysregulation directly, and by making a call for 
new transcriptomic data that comprise large female cohorts.
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1 Introduction
Autism Spectrum Disorder (ASD) is a markedly heterogeneous condition with a varied 
phenotypic presentation and a spectrum of disability for those affected. As a 
neurodevelopmental disorder, the ASD syndrome is characterised by social abnormalities, 
language abnormalities, and stereotyped behavioural patterns [Bailey et al. (1996)]. The 
presence of a genetic link in ASD etiology is well- established [Miles (2011); Miyauchi and 
Voineagu (2013)], as first evidenced by ASD concordance among siblings and by a clear 
association between ASD and specific genetic disorders (e.g., Fragile X mental retardation) 
[Bailey et al. (1996)]. This link has prompted a number of transcriptomic studies (e.g., 
[Hertz-Picciotto et al. (2006); Glatt et al. (2012); Gupta et al. (2014a)]) to identify gene 
expression signatures as a biomarker that might help elucidate the etiology of ASD and aid 
in its diagnosis (an important objective since early diagnosis and therapy is shown to 
improve outcomes in ASD [Elder et al. (2017)]). However, despite the number of 
transcriptomic studies performed, the pathophysiology and biomarker profile of ASD are 
still not known. Rather, these studies have tended to produce inconsistent results, suggesting 
wide heterogeneity among both the individual patients and the study populations, although 
several studies have converged to find associations among neuron-specific genes [Gupta et 
al. (2014b); Parikshak et al. (2016); Voineagu et al. (2011)]. Indeed, ASD may not have one 
signature at all, but instead multiple diverging signatures [Tylee et al. (2017a)].
Transcriptomic studies of ASD probands typically use cells collected from either post-
mortem brains or blood in order to estimate the mRNA abundance for thousands of gene 
transcripts, by way of microarray technology or massively parallel high-throughput 
sequencing (RNA-Seq). Since many expressed transcripts are a precursor to structural or 
functional proteins, these studies can provide an insight into the functional state of a cell, 
capturing the common pathway for hereditary predisposition and environmental exposure. 
Although post-mortem brain studies have an advantage in that they look directly at the tissue 
of interest, blood-based studies can identify clinically useful biomarkers while also serving 
as a reliable proxy for gene expression in the brain [Tylee et al. (2013)], though a complete 
understanding of ASD pathophysiology and its biomarker profile will likely require careful 
consideration of both lines of evidence. To date, more than a dozen studies have measured 
the transcriptomic profiles of ASD probands and controls, the results of which have been 
summarised by two separate meta-analyses [Ch’ng et al. (2015); Ning et al. (2015)] and one 
mega-analysis [Tylee et al. (2017a)].
Sex is often called a risk factor for ASD, and it is stated that the risk for a male to have ASD 
is four to five times higher than that for females [Werling et al. (2016); Christensen et al. 
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(2016)] (although the magnitude of this difference may be partly due to diagnostic biases 
[Lai et al. (2015)]). A similar observation, that the increased male risk is even higher among 
high-functioning ASD probands [Fombonne (1999)], likewise suggests that sex-specific 
mechanisms could influence ASD pathophysiology and its biomarker profile. Further 
evidence for sex-specific mechanisms is found in recent transcriptomic and functional-
imaging studies. For example, Tylee et al., using transformed lymphoblastoid cell lines, 
found evidence for sex-specific differential regulation of genes and pathways among ASD 
probands [Tylee et al. (2017)]. Similarly, Trabzuni et al. found sex-specific differences in 
alternative splicing in adult human brains, including for a well-known ASD risk gene 
NRXN3 [Trabzuni et al. (2013)]. Functional brain connectivity studies using fRMI imaging 
have also identified sexual heterogeneity among ASD probands, showing dysregulation in 
sexually dimorphic brain regions across two large studies [Floris et al. (2018); Lai et al. 
(2013)]. Moreover, recent work by Mitra et al. found evidence for pleiotropy between 
common single nucleotide polymorphisms (SNPs) for secondary sex characteristics and 
ASD risk, as well as sex heterogeneity on the X-chromosome, through a comprehensive 
SNP mega-analysis combining 12 individual data sets from diverse genetic backgrounds 
[Mitra et al. (2016)]. Taken together, it seems plausible that sex could interact with other 
genetic and environmental factors to create sex-specific ASD pathophysiologies and 
biomarker profiles.
As ASD is more common in males, it suggests that females may have some underlying 
protection whereby a higher risk load is required for them to become afflicted [Robinson et 
al. (2013)]. One hypothesis posits that ASD itself reflects a shift towards “extreme 
maleness” such that males are necessarily predisposed [Baron-Cohen (2002)]. In support of 
this, females with ASD do harbour more and larger copy number variants than males with 
ASDs [Levy et al. (2011)], and moreover exhibit differential penetrance given the same 
genetic etiology [Lionel et al. (2014)], although Mitra et al. found no evidence for an 
increased SNP load in females [Mitra et al. (2016)]. Unfortunately, however, the increased 
prevalence of ASD in males has led to the exclusion of females from many transcriptomic 
studies (e.g., [Hu et al. (2009); Sarachana et al. (2010); Alter et al. (2011)]), making it 
difficult to understand the male skew in ASD prevalence. Indeed, individual studies are often 
underpowered to detect subtle sex-specific differences, if they contain female subjects at all. 
When female subjects are included, sex is typically modelled as a simple covariate rather 
than an ASD-sex interaction, meaning that only sex-independent, and not sex-dependent, 
biomarkers are discovered. When male ASD is contrasted with female ASD, it typically 
involves loosely comparing simple sex- specific differences in a statistically anticonservative 
manner (e.g., noting differential expression in males but not females, or vice versa). To our 
knowledge, no study has looked at whether gene expression signatures show a sex-autism 
interaction across multiple studies and human tissues.
Using a meta-analysis of six blood-based microarray data sets and an exploratory analysis of 
a single paired-end post-mortem brain RNA-Seq data set, we present an analysis of 
transcriptomic data that focuses on comparing sex-dependent and sex-independent ASD 
biomarkers across multiple tissues. By modelling the interaction of sex and ASD directly, 
we identify biomarkers and functional pathways that show sex-differences in ASD probands 
that are different than those in control subjects. Then, for those biomarkers that show no 
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interaction, we pool male and female probands to look for sex-independent biomarkers. Our 
results suggest that, despite low power, some genes have FDR-adjusted significant sex-
dependent interactions, while even more have significant sex- independent main effects. 
Subsequent pathway analysis further shows that these sex-independent biomarkers have 
substantially different biological roles than the sex-dependent biomarkers, and that some of 
these pathways are dysregulated in both post-mortem brain and blood.
2 Methods
2.1 Data acquisition
2.1.1 Microarray data—We collected multiple microarray data sets to perform a meta-
analysis of sex-autism interactions and main effects of ASD (i.e., sex-independent effects, 
where males and females are pooled). We referenced two prior meta-analyses [Ch’ng et al. 
(2015); Ning et al. (2015)], and one mega-analysis [Tylee et al. (2017a)], to prepare a list of 
data sets to study. Of these data sets, we excluded any study that (a) measured transcript 
expression from brain tissue, (b) had no female cases, (c) used cell lines (i.e., GSE37772 and 
GSE43076), or (d) treated cells (i.e., GSE32136, treated with PPA). Six data sets remained 
after exclusion, as described in Table 1.
Data acquired from the Gene Expression Omnibus (GEO) [Barrett and Edgar (2006)] (i.e., 
GSE6575 [Gregg et al. (2008)] and GSE18123 [Kong et al. (2012)]) were acquired already 
normalised and were not modified further. The other data sets (i.e., the Glatt et al. Wave I 
and Wave II data [Glatt et al. (2012)], the CHARGE study data [Hertz-Picciotto et al. 
(2006)], and the Kong et al. 2013 data [Kong et al. (2013)]) each underwent RMA 
normalization, quantile normalization, and base-2 logarithm transformation. We filtered each 
data set so that all subjects in the ASD group had a diagnosis of autism spectrum disorder. 
Some typically developing subjects from the Glatt et al. data sets were considered “Type-1 
errors”.
2.1.2 RNA-Seq data—We searched for relevant publicly available RNA-Seq data using 
the Gene Expression Omnibus (GEO) [Barrett and Edgar (2006)] with the term (“expression 
profiling by high throughput sequencing”[DataSet Type] AND (“autism spectrum disorder”
[MeSH Terms] OR “autistic disorder”[MeSH Terms])) AND “homo sapiens”[Organism] 
(query made January 2018). We restricted eligible data sets to those sequenced with paired-
end and non-poly-A-selected libraries. After excluding any data sets that used cell lines or 
did not have female cases, only one experiment, GSE107241 [Wright et al. (2017)], 
remained. These data comprise a RiboZero Gold paired-end RNA-Seq data set from 52 
postmortem dorsolateral prefrontal cortex tissue samples (10 ASD males, 3 ASD females, 
30 control males, and 9 control females). No other data met this search criteria.
Prior to alignment and quantification, raw RNA-Seq reads were trimmed using 
Trimmomatic (docker image quay.io/biocontainers/trimmomatic:0.36–4) [Bolger et al. 
(2014)] and quality control metrics were recorded (before and after trimming) using FastQC 
(docker image biocontainers/fastqc:0.11.5) [Andrews (2010)]. We aligned trimmed reads 
and quantified expression using Salmon (docker image combinelab/salmon:0.9.0) [Patro et 
al. (2017)] as run in pseudo-quantification mode with a k-mer index of length 31. For the 
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reference, we concatenated a human coding reference (i.e., GRCh38.90.cds) with the 
corresponding non-coding reference (i.e., GRCh38.90.ncrna).
2.2 Meta-analysis of microarray data
Before proceeding with the meta-analysis, we established a set of probes for each 
microarray platform that represent genes also represented by probes in the other platforms. 
In other words, we established a final probe set based on the intersection of unique gene 
symbols present in all microarray platforms under study.
For each microarray data set, and for each probe (i.e., of those representing genes found in 
all data sets), we performed differential expression analysis using limma (Version 3.34) 
[Smyth (2004)], applying the following steps: (1) fit a single model with the formula ~ASD 
+ Sex + ASD:Sex + Age where ASD and Sex are each two-level factors (except GSE6575, 
where the Age covariate is unknown), (2) define contrasts for the sex-autism interaction and 
for the sex-independent main effects, and (3) measure the differential expression for each 
contrast using the eBayes procedure. In other words, we fit a single model but pulled out the 
appropriate contrasts in two steps.
Next, we transformed platform-specific probe p-values to HGNC symbol p-values using 
AnnotationDbi (available from Bioconductor [Huber et al. (2015)]). We resolved many-to-
one mapping ambiguities by FDR-adjusting the minimum p-value of all probes for a given 
gene symbol (i.e., calculating a within-gene FDR correction). We then used Fisher’s method 
to perform a meta-analysis of the p-values obtained from the differential expression analysis. 
For K studies, Fisher’s method scores each gene based on negative two times the sum of the 
logarithm of the p-values:
χ2K
2 = − 2∑
i
K
logpi
This score follows a χ2 distribution with 2K degrees of freedom [Mosteller and Fisher 
(1948)]. Thus, for each gene, we computed a p-value directly from this score. We corrected 
for multiple testing using the Benjamini-Hochberg procedure [Benjamini and Hochberg 
(1995)].
2.3 Differential expression analysis of RNA-Seq data
We used DESeq2 (Version 3.6) [Love et al. (2014)] to test for differential transcript 
expression within the Salmon-generated counts. We applied a conservative expression filter 
(i.e., at least 10 estimated counts per-gene in every sample) to the raw count matrix to ensure 
that the high variability of lowly expressed transcripts did not bias results due to the small 
group sizes. For each transcript that passed the expression filter, a single model was fit using 
the formula ~ASD + Sex + ASD:Sex + Age (where Age is the age of death). Interaction and 
sex-independent main effects were then extracted from the model by specifying the relevant 
contrasts to the DESeq2::results function. Again, we fit a single model but pulled out the 
appropriate contrasts in two steps. We corrected for multiple testing using the Benjamini-
Hochberg procedure [Benjamini and Hochberg (1995)].
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2.4 Adjustment of latent batch effects
To ensure that latent batch effects did not inflate the discovery of false positives, we 
performed all analyses above with adjustment for batch effects using sva (Version 3.26) 
[Leek et al. (2012); Leek (2014)], applying the following steps: (1) estimate the number of 
surrogate variables while specifying the ASD * Sex interaction as the variable of interest 
(via a 4-level factor that contains ‘MaleASD’, ‘FemaleASD’, ‘MaleControl’, and 
‘FemaleControl’) and Age as an adjustment variable, (2) use the sva function (or, in the case 
of Salmon-generated counts, the svaseq function) to estimate the surrogate variables, and (3) 
include the surrogate variables in the differential expression model(s) described above. 
Generally speaking, using sva yielded more conservative results than not using sva. All 
tables and figures show results generated with sva except where otherwise noted.
2.5 Pathway analysis and knowledge integration
We performed pathway analysis using GSEA (Version 3.0) [Subramanian et al. (2005)] in 
PreRanked mode with classic enrichment and 1,000 permutations. Enrichment scores were 
calculated for specific MSigDB (Version 6.1) [Subramanian et al. (2005); Liberzon et al. 
(2011)] gene sets, including the curated KEGG (c2.cp.kegg [Kanehisa et al. (2017)]), Gene 
Ontology Biological Process (c5.bp) [The Gene Ontology Consortium (2017)], Reactome 
(c2.cp.reactome) [Fabregat et al. (2018)], and MSigDB Hallmark (h.all) [Liberzon et al. 
(2015)] sets.
Based on the nature of the analyses, input rank lists were prepared differently for the RNA-
Seq and microarray results. For the RNA-Seq analysis, we ranked transcripts based on the p-
value, p, and the direction of the fold-change, FC:
Rank = − log10(p) × sign(log2(FC))
where positive FC refers to up-regulation in ASD for the sex-independent main effects. 
Then, these transcript-level ranks were converted into gene-level ranks based on the top 
transcript-level rank. For the microarray meta-analysis, we ranked genes using the χ2 test 
statistic (as calculated from Fisher’s method). Note that since this latter metric is agnostic to 
the direction of expression changes (i.e., only large χ2 test statistics suggest dysregulation), 
we focused here on pathways enriched with a positive score (effectively making this 
pathway enrichment test one-tailed). In both cases, we set α = 0.30.
3 Results
3.1 Evidence for sex-dependent autism biomarkers
By modelling the sex-autism interaction directly, we can detect gene expression signatures 
that have differential dysregulation in male ASD probands when compared with female ASD 
probands. In other words, we can find sexually dimorphic ASD biomarkers (e.g., a gene up-
regulated in male ASD but not in female ASD, or vice versa). Despite small study sizes, and 
disproportionately fewer females, we find some evidence for a sex-autism interaction among 
biomarkers, especially throughout the microarray meta-analysis data.
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From the analysis of the RNA-Seq data derived from post-mortem brain tissue, we find no 
transcripts with significant (FDR-adjusted p-value < 0.05) sex-dependent dysregulation, 
although one of these transcripts showed a significant interaction prior to batch correction 
with sva. To illustrate what a sex-autism interaction might look like, Figure 1 shows the per-
group expression profiles for the two transcripts with the largest interaction effect (i.e., those 
with the smallest corrected p-value). Table 2 characterises those transcripts with the most 
sex-dependent dysregulation.
From the meta-analysis of the blood-based microarray data, we find four genes with 
significant (FDR-adjusted) sex-dependent dysregulation: TTF2, UTY, KCNJ8, and NCS1. 
Table 3 characterises those genes with the most sex-dependent dysregulation. For Fisher’s 
method, a very small p-value in only one study could cause the meta-analysis to post a 
significant result [Tseng et al. (2012)]. Therefore, it is useful to inspect visually how each 
study contributed to the results of the meta-analysis. Figure 2 shows how each study 
contributed to the meta-analysis findings by plotting the aggregate Fisher score for each 
gene with large sex-dependent dysregulation, along with the study-wise nominal 
significance (unadjusted p-value < 0.05). Notably, several of the most significantly 
dysregulated genes are at least nominally significant in more than one study.
3.2 Evidence for sex-independent autism biomarkers
In situations where a sex-autism interaction is not detectable, we can proceed to measure 
sex- independent main condition effects by pooling male ASD probands with female ASD 
probands (and male controls with female controls), without having to model sex as a 
covariate. Genes with significant sex-independent main effects have large unidirectional 
effect sizes in male ASD probands, female ASD probands, or both. Yet, because the 
interaction is tested first, we can interpret the main condition effects as sex-independent.
From the analysis of the RNA-Seq data derived from post-mortem brain tissue, we find 
seven transcripts with significant (FDR-adjusted p-value < 0.05) sex-independent differential 
expression. Of these, only one transcript showed significant up-regulation in ASD (with all 
others showing down-regulation). Figure 3 shows the expression profile for the two 
transcripts with the most significant sex-independent main effects. Table 4 characterises 
those transcripts with significant sex-independent dysregulation. Interestingly, several of the 
transcripts called differentially expressed by the analysis are annotated as non-coding RNA 
species.
From the meta-analysis of blood-based microarray data, we find over 20 genes with 
significant (FDR-adjusted) sex-independent dysregulation. Table 5 characterises those genes 
with the most sex-independent dysregulation. As in Figure 2, Figure 4 shows how each study 
contributed to the meta-analysis findings by plotting the aggregate Fisher score for each 
gene with large sex- independent dysregulation, along with the study-wise nominal 
significance (unadjusted p-value < 0.05). Again, most genes selected as statistically 
significant by the meta-analysis are at least nominally significant in more than one study.
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3.3 Pathway enrichment of ASD biomarkers
In an effort to summarise the biological relevance of the biomarker profiles generated above, 
we used the complete ranked lists of the differentially expressed transcripts and genes in 
four separate gene set enrichment analyses to identify common differentially regulated 
pathways. Four enrichment profiles were generated using the sex-dependent RNA-Seq brain 
biomakers, sex-independent RNA-Seq brain biomarkers, sex-dependent microarray blood 
biomarkers, and sex-independent microarray blood biomarkers.
Figure 5 shows the KEGG pathways enriched by the biomarkers as ranked by the analysis of 
the RNA-Seq data. Interestingly, all significant enrichment occurred in the same direction. 
Figure 6 shows the KEGG pathways enriched by the biomarkers as ranked by the analysis of 
the microarray data. Unlike the RNA-Seq enrichment analysis, the meta-analysis enrichment 
analysis is agnostic to direction. Figure 7 compares the overlap between these significant 
pathways. For the sex-dependent analyses, no pathways are enriched in both the RNA-Seq 
and microarray data. However, for the sex-independent analyses, two pathways are enriched 
in both data (i.e., Ribosome and Proteasome), though this observation might have occurred 
by chance. Note that we also tested for enrichment among the Gene Ontology Biological 
Process, Reactome, and MSigDB Hallmarks gene sets, all of which show more examples of 
overlap between the separate sex-independent analyses (see the Supplementary Information 
for more details). We make the complete pathway enrichment results for the interaction and 
main effects found in the RNA-Seq and microarray data sets all available at at https://
doi.org/10.5281/zenodo.1421429.
4 Discussion
In this report, we present an analysis of several ASD transcriptomic studies, including a 
meta- analysis of six blood-based microarray data sets and an exploratory analysis of RNA-
Seq data derived from post-mortem brain. In both analyses, we focus on identifying sex-
dependent and sex-independent biomarker profiles for ASD by modelling the sex-autism 
interaction directly. In addition to identifying transcript and gene biomarkers, we use gene 
set enrichment analysis to summarise the observed dysregulation at the pathway level, 
contrasting sex-dependent pathway enrichment with sex-independent pathway enrichment. 
In doing so, we find that some pathways are across both tissues (i.e., Ribosome and 
Proteasome), though this observation might have occurred by chance.
Despite small sample sizes in all studies, we found evidence for the existence of some sex- 
dependent biomarkers in human tissue. The meta-analysis identified four genes with 
significant (FDR-adjusted) sex-dependent dysregulation in the blood: TTF2, UTY, KCNJ8, 
and NCS1. One of these, TTF2, plays an important role in normal thyroid development [De 
Felice and Di Lauro (2004)]. Interestingly, a loss of thyroid hormone homoeostasis has been 
linked to ASD [Berbel et al. (2014); Khan et al. (2014)]. Since it is well-known that thyroid 
diseases have a sex-specific presentation [Bauer et al. (2014)], it seems plausible that thyroid 
abnormalities could contribute to a sexually dimorphic ASD signature. Some thyroid-
disrupting environmental chemicals have also been linked to an altered risk for autism [Lyall 
et al. (2017); Braun et al. (2014)], including one study showing sexually dimorphic 
associations [Lyall et al. (2017)]. The other, U T Y , is a Y-chromosome gene (with 
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considerable homology to an X-chromosome homolog), making any interpretation of its 
differential dysregulation difficult. Two other genes, KCNJ8 and NCS1, are involved in 
potassium and calcium channel activity, respectively, the latter of which has been implicated 
in autism [Handley et al. (2010)]. Although the RNA-Seq analysis did not yield any 
significant interactions, it is not surprising considering this data set contained only three 
female ASD probands. Nevertheless, the large (albeit non-significant) effect sizes warrant 
repeat studies with bigger cohorts and more female ASD probands.
By modelling the sex-autism interaction directly, we are able to follow-up the sex-dependent 
analysis with a secondary sex-independent analysis for any transcript or gene whose 
expression did not significantly interact with sex. Using the same regression model, we 
contrast the pooled male ASD probands and female ASD probands against the pooled male 
controls and female controls to calculate the main effects (which we can interpret as sex-
independent biomarkers). Here, over twenty transcripts and genes exceeded the threshold for 
FDR-adjusted significance. Interestingly, for the RNA-Seq data, several of the significant 
biomarkers are not protein-coding genes, highlighting the value of using non-poly-A-
selected libraries to quantify both coding and non-coding transcripts. For the microarray 
meta-analysis, several of the sex-independent biomarkers are associated with key 
neurodevelopmental processes, including some X-chromosome genes. For example, 
MAGED2, differentially expressed in ASD probands, is located on an X-linked intellectual 
disability hotspot (i.e., Xp11.2) [Langnaese et al. (2001); Moey et al. (2016)] which, if 
causally relevant, could contribute to the male risk bias.
For both the microarray meta-analysis and the RNA-Seq analysis, we tested the ranked sex- 
dependent and sex-independent biomarker profiles separately for pathway-level enrichment. 
We found some pathway enrichment for the sex-dependent profiles, and even more for the 
sex-independent profiles. Importantly, very few of the enriched pathways were the same for 
both the interaction and main effects. This suggests that males and females exhibit unique 
pathway-level signatures that, if causally relevant, might further suggest the existence of 
both sex-specific and common ASD pathophysiologies. Although few KEGG pathways are 
enriched among the sex-dependent results, there are dozens of significantly enriched sex-
dependent pathways across other tested gene sets (see Supplementary Information for more 
details). Among the pathways enriched in the sex- independent meta-analysis results, there 
are a number of pathways for known neurodevelopmental and neurodegenerative diseases, 
including Huntingtons, Parkinsons, Alzheimers, and amyotrophic lateral sclerosis (ALS), 
suggesting that at least some of these ASD biomarkers may have functions important to 
general brain health. Considering that the sex-dependent and sex-independent biomarkers 
and pathways differ, it seems plausible that molecular diagnostics could benefit from 
modelling sex-specific processes directly.
In addition to finding that pathway enrichment differs considerably between the sex-
dependent and sex-independent biomarker profiles, we found that some sex-independent 
pathways (e.g., Ribosome and Proteasome) were enriched across both the RNA-Seq and 
microarray data. Interestingly, this overlap exists despite the fact that analyses were 
performed on different human tissues, and with different transcript quantification assays. In 
fact, more than fifty Gene Ontology pathways were enriched among both sets of ranked sex-
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independent biomarkers, even though no gene products showed significant differential 
expression in both data. This overlap is consistent with a broad literature supporting 
common pathway-level signatures across the widely heterogeneous population of ASD 
probands. If true, it may be advantageous to model pathway-level dysregulation directly, for 
example in machine learning applications Quinn et al. (2018).
When we compare our pathway enrichments to the previous ASD mega-analysis pathway 
enrichments [Tylee et al. (2017b)], we observe several complementary results. First, we 
found positive enrichment of the MAPK pathway in our sex-dependent RNA-Seq results, 
agreeing with the male- specific enrichment of Mek targets found in the Tylee et al. study 
[Tylee et al. (2017b)]. Second, we found an enrichment of the ribosome-related pathway in 
both of our sex-independent analyses, agreeing with the ribosome-related pathway 
enrichment identified by the sex-independent mega-analysis [Tylee et al. (2017b)]. Third, we 
found an enrichment of the Toll-like receptor (TLR) signalling pathway in our sex-
independent meta-analysis results, agreeing with the TLR 3 and 4 signalling pathway 
enrichment identified by the sex-independent mega-analysis [Tylee et al. (2017b)]. 
Importantly, these complementary results exist despite considerable differences in statistical 
methodology and data set inclusion. The Wright et al. study which generated the RNA-Seq 
study did not test for KEGG enrichment. However, we both found SNORD17 to be 
differentially expressed independent of sex [Wright et al. (2017)].
Our analysis is not without limitations. First, although we used sva to adjust for latent batch 
effects, it is still possible that some residual batch effects remain because they coincide with 
the diagnostic label (e.g., undocumented co-morbidities or medication use). This would 
confound the discovered biomarker profile, causing spurious results. Second, as with any 
observational study, it is impossible to conclude whether the gene expression signatures, and 
their associated pathways, are causally related to ASD. Third, this analysis is likely under-
powered to detect all sex-autism interactions, owing to the small sample sizes and 
disproportionately smaller female cohorts. Yet, based on the extant literature, which clearly 
highlights sex as an ASD risk factor, and the results published here, we believe that 
modelling the sex-autism interaction should become a mainstay of ASD transcriptomic 
research. Advantageously, interaction modelling is compatible with the most commonly 
used softwares for batch-effect correction [Leek et al. (2012)], RNA-Seq analysis [Love et 
al. (2014)], and microarray analysis [Smyth (2004)]. Yet, this analytical technique cannot 
offer any benefit if transcriptomic studies continue to systematically exclude female subjects 
(e.g., [Hu et al. (2009); Sarachana et al. (2010); Alter et al. (2011)]). Although there seems 
to exist a strong skew in the prevalence of male ASD, this very fact underlies the importance 
of studying female ASD: a complete understanding of the molecular basis of ASD will 
require the intentional study of both sex-dependent and sex-independent mechanisms, as 
well as their differences and commonalities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
These violin plots show the base-2 logarithm-transformed expression for the two transcripts 
with the largest interaction effect from the RNA-Seq data (i.e., those with the smallest 
corrected p-value). The solid lines show sex-specific mean expression differences. The 
dashed line shows the sex-independent (i.e., pooled) mean expression difference. The left 
and right transcripts are associated with the DSP and SLC13A4 genes, respectively.
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Figure 2: 
This figure shows the genes with the most significant sex-dependent dysregulation (i.e., a 
sex-autism interaction) according to the meta-analysis of the microarray data. Above, the bar 
plot shows the χ2 score for each gene as calculated using Fisher’s method (where the dark 
bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows 
whether a gene showed a nominally significant sex-dependent dysregulation at an 
unadjusted p-value < 0.05 for a given study. Note that most genes selected for by the meta-
analysis show at least nominal significance across multiple studies.
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Figure 3: 
These violin plots show base-2 logarithm-transformed expression for the two most 
significant main effects (i.e., of the ASD condition) from the RNA-Seq data. The solid lines 
show sex-specific mean expression differences. The dashed line shows the sex-independent 
(i.e., pooled) mean expression difference. The left and right transcripts are associated with 
the SNORD17 and RN U 2 − 2P genes, respectively.
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Figure 4: 
This figure shows the genes with the most significant sex-independent main effects (i.e., of 
the ASD condition) according to the meta-analysis of the microarray data. Above, the bar 
plot shows the χ2 score for each gene as calculated using Fisher’s method (where the dark 
bars indicate that the gene has an FDR-adjusted p-value < 0.05). Below, the dot plot shows 
whether a gene showed a nominally significant sex-independent main effect at an unadjusted 
p-value < 0.05 for a given study. Note that most genes selected for by the meta-analysis 
show at least nominal significance across multiple studies.
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Figure 5: 
This dot plot shows results from a GSEA of the RNA-Seq data against the MSigDB KEGG 
pathways. For the sex-autism interaction and the main effect results, a KEGG pathway (y-
axis) has a circle (or triangle) if it is enriched (or depleted). The size of the points indicates 
the absolute normalised enrichment score. The colour indicates the FDR. Note that only 
points with an FDR < 0.3 are plotted (see Methods). The enrichment score is defined as the 
degree to which a gene set is over-represented at the top or bottom of a ranked gene list as 
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calculated by GSEA. The ratio of this to the expected enrichment score of all permutations 
is the normalised enrichment score (NES).
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Figure 6: 
This dot plot shows results from a GSEA of the meta-analysis data against the MSigDB 
KEGG pathways. For the sex-autism interaction and the main effect results, a KEGG 
pathway (y-axis) has a circle if it is enriched. The size of the points indicates the absolute 
normalised enrichment score. The colour indicates the FDR. Note that only points with an 
FDR < 0.3 are plotted (see Methods). The enrichment score is defined as the degree to which 
a gene set is over- represented at the top or bottom of a ranked gene list as calculated by 
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GSEA. The ratio of this to the expected enrichment score of all permutations is the 
normalised enrichment score (NES).
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Figure 7: 
This UpSet plot [Lex et al. (2014)] shows set intersections (and their sizes) from a GSEA of 
four results against the MSigDB KEGG pathways. Set identity is indicated by the joined 
lines. Set size is indicated by the top bar chart. The bar chart on the left shows the total set 
size for each individual GSEA run. Results are filtered using a liberal FDR threshold of FDR 
< 0.15 for the RNA-Seq data and FDR < 0.3 for the meta-analysis data (see Methods).
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Table 1:
This table details all studies included in the meta-analysis, and the number of probes available after 
establishing a final probe set. We filtered each data set so that all subjects in the ASD group had a diagnosis of 
autism spectrum disorder. Some typically developing subjects from the Glatt et al. data sets were considered 
“Type-1 errors”.
Study ID Probes (Intersect) Females (TD) Males (TD) Females (ASD) Males (ASD)
GSE6575 39561 3 9 8 36
GSE18123 19532 34 48 24 80
Glatt et al. Wave I 28424 28 40 11 49
Glatt et al. Wave II 28424 35 56 28 85
CHARGE 39561 15 75 15 103
Kong et al. 2013 19532 7 10 7 46
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Table 2:
This table shows SVA-adjusted results for the sex-autism interaction for the RNA-Seq data (sorted by FDR-
adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed without the 
adjustment of latent batch effects.
Transcript ID Gene symbol Transcript biotype Log 2 FC P-adj SVA P-adj (no SVA)
ENST00000354042 SLC13A4 protein coding 3.27 0.293 0.1136846
ENST00000379802 DSP protein coding 3.19 0.293 0.6534814
ENST00000262551 OGN protein coding 2.97 0.299 0.8169099
ENST00000371625 PTGDS protein coding 1.74 0.299 0.0329544
ENST00000223357 AEBP1 protein coding 1.85 0.529 0.8713166
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Table 3:
This table shows genes with the most sex-dependent dysregulation (and their chromosomal position) for the 
meta-analysis results, sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher 
score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.
Location Fisher Fisher p-adj Fisher (no SVA) Fisher p-adj (noSVA)
TTF2 1p13.1 52.80272 0.0080909 30.30688 1.0000000
UTY Yq11.221 49.17813 0.0352693 45.32043 0.1644908
KCNJ8 12p12.1 48.80700 0.0409512 41.60015 0.7040022
NCS1 9q34.11 48.69443 0.0428454 33.16947 1.0000000
RAP2C Xq26.2 47.97863 0.0571022 25.06737 1.0000000
CHST11 12q23.3 47.29425 0.0750785 21.86910 1.0000000
MAP1B 5q13.2 47.18032 0.0785676 44.44789 0.2320088
CRHR1 17q21.31 47.15296 0.0794259 43.43498 0.3450932
PAFAH1B1 17p13.3 46.36425 0.1087281 17.26173 1.0000000
SH3BGR 21q22.2 46.35975 0.1089168 32.82178 1.0000000
PAK3 Xq23 45.67211 0.1430652 46.45645 0.1048620
FMO1 1q24.3 44.77510 0.2038808 32.85009 1.0000000
TROVE2 1q31.2 44.42306 0.2341680 21.84958 1.0000000
BNC2 9p22.3-p22.2 44.40285 0.2360233 39.13101 1.0000000
DCUN1D1 3q26.33 44.08602 0.2672865 40.02468 1.0000000
HECA 6q24.1 44.06996 0.2689620 33.92752 1.0000000
RORA 15q22.2 43.52061 0.3335278 34.11106 1.0000000
ARHGAP35 19q13.32 43.40139 0.3494222 41.54671 0.7186470
CAMK1D 10p13 43.34605 0.3570412 23.46336 1.0000000
SLC27A6 5q23.3 43.26356 0.3687130 42.46235 0.5041354
SNX13 7p21.1 43.07811 0.3963678 27.35225 1.0000000
ACKR2 3p22.1 43.06703 0.3980622 36.05068 1.0000000
KCNN2 5q22.3 42.76385 0.4479560 44.03212 0.2731511
TEX35 1q25.2 42.72490 0.4547740 40.79263 0.9608426
TMEM56 1p21.3 42.56794 0.4833811 34.90678 1.0000000
SYTL4 Xq22.1 42.49851 0.4965789 40.68910 0.9997724
AZGP1 7q22.1 42.48820 0.4985441 27.40362 1.0000000
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Table 4:
This table shows SVA-adjusted results for the main effects (i.e., of the ASD condition) for the RNA-Seq data 
(sorted by FDR-adjusted p-value). Note that FDR-adjusted p-values are also shown for an analysis performed 
without the adjustment of latent batch effects.
Transcript ID Gene symbol Transcript biotype Log 2 FC P-adj (SVA) P-adj (no SVA)
ENST00000390930 SNORD17 snoRNA −2.98 1.54e-05 0.0000102
ENST00000410396 RNU2-2P snRNA −4.76 4.04e-05 0.0000000
ENST00000613119 snRNA −3.23 9.18e-05 0.0000000
ENST00000258526 PLXNC1 protein coding 0.48 0.00468 0.4273372
ENST00000393775 IGSF11 protein coding −1.18 0.00468 1.0000000
ENST00000459255 SCARNA10 snoRNA −1.71 0.00468 0.0014803
ENST00000618786 RN7SL1 misc RNA −1.35 0.0124 0.0026454
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Table 5:
This table shows genes with the most sex-independent dysregulation (and their chromosomal position) for the 
meta-analysis results, sorted by Fisher score and adjusted p-value. In addition, this table shows the Fisher 
score and adjusted p-value calculated for an analysis repeated without the adjustment of latent batch effects.
Location Fisher Fisher p-adj Fisher (no SVA) Fisher p-adj (noSVA)
ARHGAP35 19q13.32 69.93173 0.0000060 59.58783 0.0004856
GIMAP8 7q36.1 59.63083 0.0004774 52.83287 0.0079551
UCHL3 13q22.2 55.73392 0.0024208 26.61452 1.0000000
SPART 13q13.3 55.39389 0.0027862 42.18348 0.5444711
MAGED2 Xp11.21 54.65897 0.0037735 31.43801 1.0000000
ZNF721 4p16.3 54.38812 0.0042188 46.99662 0.0833787
TCEAL8 Xq22.1 54.30254 0.0043699 31.39363 1.0000000
KIF13B 8p12 53.86902 0.0052226 44.83078 0.1953472
COX19 7p22.3 51.12904 0.0160066 51.00574 0.0167250
POLR1A 2p11.2 50.82535 0.0181073 32.52993 1.0000000
NUCB2 11p15.1 50.20003 0.0233305 49.91295 0.0260057
EIF3A 10q26.11 49.84351 0.0269484 47.30791 0.0736972
GNG5 1p22.3 49.73328 0.0281743 23.65365 1.0000000
HNRNPA3P1 10q11.21 49.54482 0.0304006 51.23881 0.0152201
KLF1 19p13.13 49.43419 0.0317868 35.96265 1.0000000
GNPDA1 5q31.3 48.90133 0.0393978 41.09008 0.8257563
SART3 12q23.3 48.88131 0.0397143 52.43134 0.0093729
CCNC 6q16.2 48.87932 0.0397440 16.14519 1.0000000
UBE2A Xq24 48.87429 0.0398222 23.54974 1.0000000
ESF1 20p12.1 48.70005 0.0427109 39.78234 1.0000000
ZNF740 12q13.13 48.63177 0.0438971 46.72013 0.0930420
MTERF4 2q37.3 48.49211 0.0464282 37.44203 1.0000000
CCP110 16p12.3 47.96099 0.0574500 28.55662 1.0000000
JUND 19p13.11 47.85553 0.0599253 37.46297 1.0000000
MTERF1 7q21.2 47.82145 0.0607453 29.44710 1.0000000
ZNF569 19q13.12 47.57334 0.0670814 36.67860 1.0000000
PGM1 1p31.3 46.90219 0.0876872 37.26441 1.0000000
ECI2 6p25.2 46.79028 0.0916801 51.52112 0.0135729
ARHGAP8 22q13.31 46.67208 0.0960926 46.17090 0.1155403
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